David Portman, MD, Sermonix CEO and chief medical officer, was a principal investigator for the phase 2 and 3 lasofoxifene trials and a consultant during drug development. Dr Portman has experience in all stages of the regulatory approval process and has worked with the FDA on numerous pre-approval and approval meetings, advisory committees, and submission and approval considerations. He has worked with the medical, marketing, launch, and sales aspects of many products in the women’s healthcare space.
Current role
CEO & Chief Medical Officer at Cerebral
CEO & Chief Medical Officer at MedTherapy Biotech
CEO, Chief Medical Officer, Director & Founder at Eyenovia
Founder, CEO & Chief Medical Officer at OncoSynergy
Co-President, CEO & Chief Medical Officer at St. Luke’s